Image Place holder

Jason Brayer, MD, PhD

Specialty: Hematology/Oncology

Program: Malignant Hematology

Overview


Associations

    • Malignant Hematology
    • Immunology
    • Immuno-Oncology
    • Immuno-Oncology

Education & Training

Graduate:

  • University of Florida - PhD - Medical Science (Immunology)

Board Certification:

  • Internal Medicine

Fellowship:

  • La Jolla Institute of Allergy & Immunology, Fellow - Immunology
  • H. Lee Moffitt Cancer Center and Research Institute, Fellow -
  • H. Lee Moffit Cancer Center and Research Institute, Fellow - Hematology/Oncology

Residency:

  • University of South Florida - Internal Medicine

Medical School:

  • University of South Florida - MD
Research

My research interests include:• Exploring the therapeutic potential of HDAC11 inhibitors in the treatment of multiple myeloma.• Exploring the potential for selective HDAC11 inhibitors to enhance T cell responses in the context of immunotherapy, including vaccine-based and cellular adoptive therapeutic approaches.• Defining the functional significance of the interaction between HDAC11 and IRF4 and its impact as a regulator of CD8 T cell function.• Defining the functional significance of the interaction between HDAC11 and IRF4 as it relates to myeloma cell development and survival.

Publications

  • Mostofa A, Distler A, Meads MB, Sahakian E, Powers JJ, Achille A, Noyes D, Wright G, Fang B, Izumi V, Koomen J, Rampakrishnan R, Nguyen TP, De Avila G, Silva AS, Sudalagunta P, Canevarolo RR, Siqueira Silva MDC, Alugubelli RR, Dai HA, Kulkarni A, Dalton WS, Hampton OA, Welsh EA, Teer JK, Tungesvik A, Wright KL, Pinilla-Ibarz J, Sotomayor EM, Shain KH, Brayer J. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight. 2021 Dec.6(24). Pubmedid: 34793338. Pmcid: PMC8783683.
  • Nakagawa R, Brayer J, Restrepo N, Mulé JJ, Mailloux AW. High-Dimensional Flow Cytometry Analysis of Regulatory Receptors on Human T Cells, NK Cells, and NKT Cells. Methods Mol Biol. 2020 Sep.2194:255-290. Pubmedid: 32926371. Pmcid: PMC7744271.
  • Baz R, Naqvi SMH, Lee JH, Brayer J, Hillgruber N, Fridley BL, Shain KH, Sullivan DM, Alsina M. Lenalidomide-based response-adapted therapy for older adults without high risk myeloma. Brit J Haematol. 2019 Mar.184(5):735-743. Pubmedid: 30548250. Pmcid: PMC7771320.
  • Sallman DA, Brayer J, Sagatys EM, Lonez C, Breman E, Agaugué S, Verma B, Gilham DE, Lehmann FF, Davila ML. NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient. Haematologica. 2018 Sep.103(9):e424-e426. Pubmedid: 29703727. Pmcid: PMC6119132.
  • Rose AM, Brayer J. Connecting the Dots: A Case of Myeloid Sarcoma. Am J Med. 2018 Sep.131(9):e357-e359. Pubmedid: 29729239.
  • Zhu G, Brayer J, Padron E, Mulé JJ, Mailloux AW. OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms. Cytometry A. 2018 Oct.93(10):982-986. Pubmedid: 30347519. Pmcid: PMC6484443.
  • Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, Odunsi K, Davila ML, Gilham DE, Lehmann FF. Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. BMJ Open. 2017 Nov.7(11):e017075. Pubmedid: 29133316. Pmcid: PMC5695348.
  • Brayer J, Baz R. The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. Ther Adv Hematol. 2017 Jul.8(7):209-220. Pubmedid: 28694935. Pmcid: PMC5495505.
  • Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am J Hematol. 2015 Jul.90(7):602-607. Pubmedid: 25802083. Pmcid: PMC4617516.
  • Dalia S, Brayer J, Horna P, Zhang H, Pinilla-Ibarz J. Transformation to Hodgkin lymphoma in chronic lymphocytic leukemia coexisting with Epstein-Barr viremia. Leuk Lymphoma. 2014 Nov.55(11):2660-2662. Pubmedid: 24528217.
  • Brayer J, Fishman M. Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment. J Immunother. 2014 Apr.37(3):187-191. Pubmedid: 24598453.
  • Brayer J, Cheng F, Wang H, Horna P, Vicente-Suarez I, Pinilla-Ibarz J, Sotomayor EM. Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. Immunol Lett. 2010 Jul.131(2):126-130. Pubmedid: 20346983. Pmcid: PMC2906450.
  • Vicente-Suarez I, Brayer J, Villagra A, Cheng F, Sotomayor EM. TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses. Immunol Lett. 2009 Aug.125(2):114-118. Pubmedid: 19555720. Pmcid: PMC2758552.
  • Horna P, Cuenca A, Cheng F, Brayer J, Wang HW, Borrello I, Levitsky H, Sotomayor EM. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood. 2006 Apr.107(7):2871-2878. Pubmedid: 16339406. Pmcid: PMC1895389.
  • Ghansah T, Paraiso K, Highfill S, Desponts C, May S, McIntosh J, Wang J, Ninos J, Brayer J, Cheng F, Sotomayor E, Kerr W. Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J Immunol. 2004 Dec.173(12):7324-7330. Pubmedid: 15585856.
  • Rodriguez P, Quiceno D, Zabaleta J, Ortiz B, Zea A, Piazuelo M, Delgado A, Correa P, Brayer J, Sotomayor E, Antonia S, Ochoa J, Ochoa A. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004 Aug.64(16):5839-5849. Pubmedid: 15313928.
  • Cheng F, Wang H, Cuenca A, Huang M, Ghansah T, Brayer J, Kerr W, TakedaK, Akira S, Schoenberger S, Yu H, Jove R, Sotomayor E. A critical role for Stat3 signaling in immune tolerance. Immunity. 2003 Sep.19(3):425-436. Pubmedid: 14499117.
  • Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L, Bien H, Borrello I, Levitsky H, Sotomayor E. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 2003 Dec.63(24):9007-9015. Pubmedid: 14695219.

Grants

  • Title: Characterization of Evolving Immune Profiles of Marrow-Infiltrating Lymphocytes Engineered to Express a BCMA-Targeting Chimeric Antigen Receptor
    Sponsor: WindMIL Therapeutics
    PI: Brayer, J.
  • Title: Translating phenotype to function to predict efficacy of immunotherapeutic efficacy
    Sponsor: BD Biosciences
    PI: Brayer, J.